JP2022120125A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022120125A5 JP2022120125A5 JP2022095460A JP2022095460A JP2022120125A5 JP 2022120125 A5 JP2022120125 A5 JP 2022120125A5 JP 2022095460 A JP2022095460 A JP 2022095460A JP 2022095460 A JP2022095460 A JP 2022095460A JP 2022120125 A5 JP2022120125 A5 JP 2022120125A5
- Authority
- JP
- Japan
- Prior art keywords
- ylvinyl
- pyrrolidin
- pyrimidine
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000003839 salts Chemical class 0.000 claims 37
- FNEHSHNEXMPCLJ-VWCDRPFISA-N 5-[(e)-2-[(3r)-pyrrolidin-3-yl]ethenyl]pyrimidine Chemical compound C1NCC[C@@H]1\C=C\C1=CN=CN=C1 FNEHSHNEXMPCLJ-VWCDRPFISA-N 0.000 claims 33
- 239000008194 pharmaceutical composition Substances 0.000 claims 32
- 238000001356 surgical procedure Methods 0.000 claims 8
- 239000000825 pharmaceutical preparation Substances 0.000 claims 6
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims 4
- 206010052143 Ocular discomfort Diseases 0.000 claims 4
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims 4
- 206010013774 Dry eye Diseases 0.000 claims 2
- 208000002193 Pain Diseases 0.000 claims 2
- 239000007788 liquid Substances 0.000 claims 2
- 239000006210 lotion Substances 0.000 claims 2
- -1 pyrrolidin-3-ylvinyl Chemical group 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 108010019783 tear proteins Proteins 0.000 claims 2
- HBHGGCJSXUZORP-NLPRBWRTSA-N (2S,3R,4S,5R)-2,3,4,5-tetrahydroxyhexanedioic acid tetrahydrate Chemical compound O.O.O=C([C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(=O)O)O.O.O HBHGGCJSXUZORP-NLPRBWRTSA-N 0.000 claims 1
- HVGZXVVUVQKTSC-OUCPDFHMSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid 5-[(E)-2-[(3R)-pyrrolidin-3-yl]ethenyl]pyrimidine Chemical group C1NCC[C@@H]1\C=C\C1=CN=CN=C1.OC(=O)CC(O)(C(O)=O)CC(O)=O HVGZXVVUVQKTSC-OUCPDFHMSA-N 0.000 claims 1
- 102100026607 ALS2 C-terminal-like protein Human genes 0.000 claims 1
- 239000000275 Adrenocorticotropic Hormone Substances 0.000 claims 1
- 208000002177 Cataract Diseases 0.000 claims 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims 1
- 102400000739 Corticotropin Human genes 0.000 claims 1
- 101800000414 Corticotropin Proteins 0.000 claims 1
- 241000021559 Dicerandra Species 0.000 claims 1
- 102400001368 Epidermal growth factor Human genes 0.000 claims 1
- 101800003838 Epidermal growth factor Proteins 0.000 claims 1
- 102100034719 Extracellular glycoprotein lacritin Human genes 0.000 claims 1
- 208000029728 Eyelid disease Diseases 0.000 claims 1
- 241000282326 Felis catus Species 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 101000717960 Homo sapiens ALS2 C-terminal-like protein Proteins 0.000 claims 1
- 101000804964 Homo sapiens DNA polymerase subunit gamma-1 Proteins 0.000 claims 1
- 101001090521 Homo sapiens Extracellular glycoprotein lacritin Proteins 0.000 claims 1
- 101000595929 Homo sapiens POLG alternative reading frame Proteins 0.000 claims 1
- 101001067189 Homo sapiens Plexin-A1 Proteins 0.000 claims 1
- 101000731732 Homo sapiens Rho guanine nucleotide exchange factor 19 Proteins 0.000 claims 1
- 101000650148 Homo sapiens WD repeat domain phosphoinositide-interacting protein 1 Proteins 0.000 claims 1
- 101000915475 Homo sapiens Zinc finger MIZ domain-containing protein 2 Proteins 0.000 claims 1
- 206010057412 Iris neoplasm Diseases 0.000 claims 1
- 101710024993 KIAA1109 Proteins 0.000 claims 1
- 108010063045 Lactoferrin Proteins 0.000 claims 1
- 102100032241 Lactotransferrin Human genes 0.000 claims 1
- 108010022337 Leucine Enkephalin Proteins 0.000 claims 1
- 206010065062 Meibomian gland dysfunction Diseases 0.000 claims 1
- 235000010654 Melissa officinalis Nutrition 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- YJBSGPVXDGLMBC-SXKXKJGMSA-N O.O.O[C@@H]([C@@H](O)[C@H](O)C(O)=O)[C@@H](O)C(O)=O Chemical compound O.O.O[C@@H]([C@@H](O)[C@H](O)C(O)=O)[C@@H](O)C(O)=O YJBSGPVXDGLMBC-SXKXKJGMSA-N 0.000 claims 1
- 208000030768 Optic nerve injury Diseases 0.000 claims 1
- 241000283973 Oryctolagus cuniculus Species 0.000 claims 1
- 102100035196 POLG alternative reading frame Human genes 0.000 claims 1
- 241000009328 Perro Species 0.000 claims 1
- 206010034960 Photophobia Diseases 0.000 claims 1
- 102100034382 Plexin-A1 Human genes 0.000 claims 1
- 102000003946 Prolactin Human genes 0.000 claims 1
- 108010057464 Prolactin Proteins 0.000 claims 1
- 208000003251 Pruritus Diseases 0.000 claims 1
- 208000002367 Retinal Perforations Diseases 0.000 claims 1
- 206010038848 Retinal detachment Diseases 0.000 claims 1
- 102100032433 Rho guanine nucleotide exchange factor 19 Human genes 0.000 claims 1
- 102100025378 Transmembrane protein KIAA1109 Human genes 0.000 claims 1
- 102100027543 WD repeat domain phosphoinositide-interacting protein 1 Human genes 0.000 claims 1
- 102100028536 Zinc finger MIZ domain-containing protein 2 Human genes 0.000 claims 1
- 239000000443 aerosol Substances 0.000 claims 1
- 208000002205 allergic conjunctivitis Diseases 0.000 claims 1
- 208000024998 atopic conjunctivitis Diseases 0.000 claims 1
- 208000010217 blepharitis Diseases 0.000 claims 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 claims 1
- 229960000258 corticotropin Drugs 0.000 claims 1
- 239000006071 cream Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940116977 epidermal growth factor Drugs 0.000 claims 1
- 239000012458 free base Substances 0.000 claims 1
- DSLZVSRJTYRBFB-DUHBMQHGSA-N galactaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O DSLZVSRJTYRBFB-DUHBMQHGSA-N 0.000 claims 1
- 239000000499 gel Substances 0.000 claims 1
- 230000007794 irritation Effects 0.000 claims 1
- 230000007803 itching Effects 0.000 claims 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 claims 1
- 229940078795 lactoferrin Drugs 0.000 claims 1
- 235000021242 lactoferrin Nutrition 0.000 claims 1
- URLZCHNOLZSCCA-UHFFFAOYSA-N leu-enkephalin Chemical compound C=1C=C(O)C=CC=1CC(N)C(=O)NCC(=O)NCC(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=CC=C1 URLZCHNOLZSCCA-UHFFFAOYSA-N 0.000 claims 1
- 239000000865 liniment Substances 0.000 claims 1
- 244000144972 livestock Species 0.000 claims 1
- 208000029233 macular holes Diseases 0.000 claims 1
- 239000007922 nasal spray Substances 0.000 claims 1
- 229940097496 nasal spray Drugs 0.000 claims 1
- 239000006199 nebulizer Substances 0.000 claims 1
- 239000002674 ointment Substances 0.000 claims 1
- 239000006072 paste Substances 0.000 claims 1
- 230000000649 photocoagulation Effects 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 229940098458 powder spray Drugs 0.000 claims 1
- 239000003755 preservative agent Substances 0.000 claims 1
- 229940097325 prolactin Drugs 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 230000004264 retinal detachment Effects 0.000 claims 1
- 230000002207 retinal effect Effects 0.000 claims 1
- 230000035807 sensation Effects 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 230000004489 tear production Effects 0.000 claims 1
- 230000001988 toxicity Effects 0.000 claims 1
- 231100000419 toxicity Toxicity 0.000 claims 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024086805A JP2024103594A (ja) | 2016-04-07 | 2024-05-29 | 眼状態の治療方法 |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662319648P | 2016-04-07 | 2016-04-07 | |
| US62/319,648 | 2016-04-07 | ||
| PCT/US2017/026385 WO2017177024A1 (en) | 2016-04-07 | 2017-04-06 | Methods of treating ocular conditions |
| JP2018553080A JP7090551B2 (ja) | 2016-04-07 | 2017-04-06 | 眼状態の治療方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018553080A Division JP7090551B2 (ja) | 2016-04-07 | 2017-04-06 | 眼状態の治療方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024086805A Division JP2024103594A (ja) | 2016-04-07 | 2024-05-29 | 眼状態の治療方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022120125A JP2022120125A (ja) | 2022-08-17 |
| JP2022120125A5 true JP2022120125A5 (enExample) | 2022-09-13 |
Family
ID=58549326
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018553080A Active JP7090551B2 (ja) | 2016-04-07 | 2017-04-06 | 眼状態の治療方法 |
| JP2022095460A Pending JP2022120125A (ja) | 2016-04-07 | 2022-06-14 | 眼状態の治療方法 |
| JP2024086805A Pending JP2024103594A (ja) | 2016-04-07 | 2024-05-29 | 眼状態の治療方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018553080A Active JP7090551B2 (ja) | 2016-04-07 | 2017-04-06 | 眼状態の治療方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024086805A Pending JP2024103594A (ja) | 2016-04-07 | 2024-05-29 | 眼状態の治療方法 |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US10709707B2 (enExample) |
| EP (2) | EP3439661B1 (enExample) |
| JP (3) | JP7090551B2 (enExample) |
| KR (2) | KR102512777B1 (enExample) |
| CN (3) | CN109310692B (enExample) |
| AU (1) | AU2017248276B2 (enExample) |
| CA (1) | CA3020170A1 (enExample) |
| DK (1) | DK3439661T3 (enExample) |
| EA (1) | EA201892265A1 (enExample) |
| ES (1) | ES2893126T3 (enExample) |
| IL (3) | IL299204A (enExample) |
| MX (2) | MX385698B (enExample) |
| MY (1) | MY199237A (enExample) |
| NZ (1) | NZ746468A (enExample) |
| PH (1) | PH12018502154A1 (enExample) |
| PT (1) | PT3439661T (enExample) |
| SG (1) | SG11201808650QA (enExample) |
| TW (2) | TWI790997B (enExample) |
| WO (1) | WO2017177024A1 (enExample) |
| ZA (1) | ZA201807438B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9145396B2 (en) | 2008-12-01 | 2015-09-29 | Targacept, Inc. | Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3ylvinyl)pyrimidine |
| PT3848028T (pt) | 2014-10-20 | 2024-09-20 | Oyster Point Pharma Inc | Métodos de tratamento de estados oculares |
| DK3439661T3 (da) | 2016-04-07 | 2021-10-18 | Oyster Point Pharma Inc | Fremgangsmåder til behandling af øjenlidelser |
| EP3820443A1 (en) | 2018-07-10 | 2021-05-19 | Oyster Point Pharma, Inc. | Combinations of positive allosteric modulators and nicotinic acetylcholine receptor agonists for treating ocular conditions |
| WO2020014217A1 (en) | 2018-07-10 | 2020-01-16 | Oyster Point Pharma, Inc. | Methods of treating ocular conditions |
| ES3039903T3 (en) * | 2020-04-28 | 2025-10-27 | Oyster Point Pharma Inc | Local administration of nicotinic acetylcholine receptor agonists for the inhibition of coronavirus infections |
| EP4333855A4 (en) * | 2021-05-07 | 2025-07-09 | Oyster Point Pharma Inc | CO-THERAPY WITH A VECTOR AND A NICOTINIC AGONIST |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6277855B1 (en) * | 2000-04-21 | 2001-08-21 | Inspire Pharmaceuticals, Inc. | Method of treating dry eye disease with nicotinic acetylcholine receptor agonists |
| US20030008892A1 (en) | 2001-07-09 | 2003-01-09 | Pfizer Inc. | Pharmaceutical composition and method of modulating cholinergic function in a mammal |
| KR20040066140A (ko) | 2001-11-29 | 2004-07-23 | 화이자 프로덕츠 인크. | 5,8,14-트리아자테트라시클로[10.3.1.0(2,11).0(4,9)]헥사데카-2(11),3,5,7,9-펜타엔의 숙신산염 및 그의 제약 조성물 |
| WO2004039366A1 (en) * | 2002-11-01 | 2004-05-13 | Pharmacia & Upjohn Company Llc | Nicotinic acetylcholine agonists in the treatment of glaucoma and retinal neuropathy |
| US7098331B2 (en) | 2003-03-05 | 2006-08-29 | Targacept, Inc. | Arylvinylazacycloalkane compounds and methods of preparation and use thereof |
| US20060270592A1 (en) | 2004-03-19 | 2006-11-30 | Ophthalmic Research Associates, Inc. | Use of neurotransmitters and neuropeptides for the treatment of dry eye diseases and related conditions |
| CA2583101A1 (en) | 2004-10-15 | 2006-04-20 | Pfizer Products Inc. | Compositions and methods for intranasal, buccal, sublingual and pulmonary delivery of varenicline |
| WO2006100075A2 (en) | 2005-03-22 | 2006-09-28 | Niconovum Ab | Use of an artificial sweetener to enhance absorption of nicotine |
| US20110086086A1 (en) | 2005-07-26 | 2011-04-14 | Pfizer Inc | Transdermal system for varenicline |
| TWI454262B (zh) | 2006-11-02 | 2014-10-01 | Targacept Inc | 菸鹼乙醯膽鹼受體亞型選擇性之二氮雜雙環烷類醯胺 |
| CA2676670C (en) | 2007-02-02 | 2012-03-13 | Pfizer Products Inc. | Tricyclic compounds, compositions, and methods |
| WO2008157365A2 (en) * | 2007-06-15 | 2008-12-24 | Targacept, Inc. | Vinylazacycloalkanes for treating neuropathic pain |
| US20090093446A1 (en) | 2007-10-05 | 2009-04-09 | Winston Laboratories, Inc. | Method for alleviating keratoconjunctivitis sicca |
| CL2008003507A1 (es) | 2007-11-26 | 2009-11-27 | Neuroderm Ltd | Composicion farmaceutica que comprende nicotina y un inhibidor de la desensibilizacion del receptor de acetilcolina nicotinico (nachr) opipramol; kit farmaceutico; dispositivo medico; y uso para tratar una enfermedad o trastorno del sistema nervioso central o periferico. |
| CA2716863A1 (en) | 2008-03-05 | 2009-09-11 | Targacept, Inc. | Sub-type selective amides of diazabicycloalkanes |
| WO2010028011A1 (en) | 2008-09-05 | 2010-03-11 | Targacept, Inc. | Amides of diazabicyclononanes and uses thereof |
| EP2344496A1 (en) | 2008-09-05 | 2011-07-20 | Targacept Inc. | Amides of diazabicyclooctanes and uses thereof |
| JP2012505834A (ja) * | 2008-10-14 | 2012-03-08 | サイコジェニックス・インコーポレーテッド | ニコチン性アセチルコリン受容体リガンドおよびその使用 |
| ES2820857T3 (es) | 2008-12-01 | 2021-04-22 | Oyster Point Pharma Inc | Síntesis y formas de sal novedosas de (R)-5-((E)-2-pirrolidin-3-ilvinil)pirimidina |
| US9145396B2 (en) * | 2008-12-01 | 2015-09-29 | Targacept, Inc. | Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3ylvinyl)pyrimidine |
| TW201024283A (en) | 2008-12-01 | 2010-07-01 | Targacept Inc | Synthesis and novel salt forms of (R)-3-((E)-2-(pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine |
| CA2763551A1 (en) * | 2009-06-17 | 2010-12-23 | Targacept, Inc. | Reversal of l-dopa-induced dyskinesia by neuronal nicotinic receptor ligands |
| US20110274628A1 (en) | 2010-05-07 | 2011-11-10 | Borschke August J | Nicotine-containing pharmaceutical compositions |
| US8821457B2 (en) | 2010-09-08 | 2014-09-02 | Johnson & Johnson Vision Care, Inc. | Punctal plug containing drug formulation |
| CA3083244C (en) | 2011-10-20 | 2023-01-03 | Novartis Ag | Biomarkers predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment |
| WO2013080196A1 (en) | 2011-11-30 | 2013-06-06 | D.E.S. Diagnostics Ltd. | Dry eye diagnostic |
| PT3848028T (pt) * | 2014-10-20 | 2024-09-20 | Oyster Point Pharma Inc | Métodos de tratamento de estados oculares |
| DK3439661T3 (da) * | 2016-04-07 | 2021-10-18 | Oyster Point Pharma Inc | Fremgangsmåder til behandling af øjenlidelser |
-
2017
- 2017-04-06 DK DK17718304.3T patent/DK3439661T3/da active
- 2017-04-06 PT PT177183043T patent/PT3439661T/pt unknown
- 2017-04-06 EP EP17718304.3A patent/EP3439661B1/en active Active
- 2017-04-06 NZ NZ746468A patent/NZ746468A/en unknown
- 2017-04-06 MX MX2018012230A patent/MX385698B/es unknown
- 2017-04-06 KR KR1020237000103A patent/KR102512777B1/ko active Active
- 2017-04-06 SG SG11201808650QA patent/SG11201808650QA/en unknown
- 2017-04-06 JP JP2018553080A patent/JP7090551B2/ja active Active
- 2017-04-06 MY MYPI2018001700A patent/MY199237A/en unknown
- 2017-04-06 EA EA201892265A patent/EA201892265A1/ru unknown
- 2017-04-06 AU AU2017248276A patent/AU2017248276B2/en active Active
- 2017-04-06 EP EP21189296.3A patent/EP3970724A1/en active Pending
- 2017-04-06 TW TW106111559A patent/TWI790997B/zh active
- 2017-04-06 CN CN201780034734.3A patent/CN109310692B/zh active Active
- 2017-04-06 KR KR1020187032218A patent/KR102485299B1/ko active Active
- 2017-04-06 IL IL299204A patent/IL299204A/en unknown
- 2017-04-06 US US16/091,830 patent/US10709707B2/en active Active
- 2017-04-06 CA CA3020170A patent/CA3020170A1/en active Pending
- 2017-04-06 CN CN202210034408.5A patent/CN114533737B/zh active Active
- 2017-04-06 CN CN202210040168.XA patent/CN114432313A/zh active Pending
- 2017-04-06 WO PCT/US2017/026385 patent/WO2017177024A1/en not_active Ceased
- 2017-04-06 ES ES17718304T patent/ES2893126T3/es active Active
- 2017-04-06 TW TW112102845A patent/TWI876258B/zh active
-
2018
- 2018-10-03 IL IL262102A patent/IL262102B/en unknown
- 2018-10-05 MX MX2021010399A patent/MX2021010399A/es unknown
- 2018-10-05 PH PH12018502154A patent/PH12018502154A1/en unknown
- 2018-11-06 ZA ZA2018/07438A patent/ZA201807438B/en unknown
-
2020
- 2020-04-17 US US16/852,225 patent/US20200345734A1/en not_active Abandoned
-
2022
- 2022-01-24 IL IL290069A patent/IL290069B2/en unknown
- 2022-06-14 JP JP2022095460A patent/JP2022120125A/ja active Pending
-
2024
- 2024-05-29 JP JP2024086805A patent/JP2024103594A/ja active Pending
- 2024-09-05 US US18/825,758 patent/US20250000861A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022120125A5 (enExample) | ||
| IL290069B1 (en) | Methods for treating eye conditions | |
| US11911380B2 (en) | Compositions and use of varenicline for treating dry eye | |
| TW201811333A (zh) | 透過腦神經之藥理皮膚活化作用來治療與神經退化性疾病相關之症狀的技術 | |
| JP2021038250A5 (enExample) | ||
| JP2023024574A5 (enExample) | ||
| US20020161013A1 (en) | Method of local anesthesia and analgesia | |
| JPH0977656A (ja) | 点眼用エアゾル組成物 | |
| CN110960485A (zh) | 一种用于治疗角膜炎的药物及其制备方法 | |
| Richa et al. | Promising implication of ocuserts in ocular disease | |
| RU2847424C1 (ru) | Контактная линза для доставки лекарственного средства | |
| RU2733392C1 (ru) | Комбинированное офтальмологическое средство | |
| Felicilda Reynaldo et al. | Evidence-Based Pharmacotherapy for Dry Eye Disease, Part 2 | |
| Pramila et al. | Review on Anjana | |
| Goldmann et al. | Therapeutic Possibilities of Using an Oxygen-Metabolism Activator (Solcoseryl®) by the Systemic and Topical Route in Ophthalmology |